Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2012

01-06-2012 | Original Article

Daily variance of urinary excretion of AQP2 determined by sandwich ELISA method

Authors: Sei Sasaki, Yasukazu Ohmoto, Toyoki Mori, Fusako Iwata, Masahiro Muraguchi

Published in: Clinical and Experimental Nephrology | Issue 3/2012

Login to get access

Abstract

Background

Urinary excretion of aquaporin 2 (AQP2) is a useful marker of kidney collecting duct function. A specific and convenient method to measure AQP2 in human urine would help to treat water balance disorders. It is unknown whether urinary excretion of AQP2 shows any daily variance.

Methods

A sandwich enzyme-linked immunosorbent assay (ELISA) method for AQP2 was established using two different kinds of antibodies, and its sensitivity and specificity were examined. Daily variance of urinary excretion of AQP2 and responses to acute water load were examined.

Results

The established ELISA specifically detected urine AQP2 with high sensitivity (detected as low as 0.34 pmol/mL). Urinary excretion of AQP2 did not show daily variance between 9 a.m. and 9 p.m. in healthy subjects.

Conclusions

The developed ELISA method using two different antibodies is convenient and highly sensitive, and could be useful in clinical practice. Urinary excretion of AQP2 is relatively constant from morning to night, and spot urine sampling at any time during this time period does not affect the results.
Literature
1.
go back to reference Noda Y, Sohara E, Ohta E, Sasaki S. Aquaporins in kidney pathophysiology. Nat Rev Nephrol. 2010;6:168–78.PubMedCrossRef Noda Y, Sohara E, Ohta E, Sasaki S. Aquaporins in kidney pathophysiology. Nat Rev Nephrol. 2010;6:168–78.PubMedCrossRef
2.
go back to reference Brown D, Katsura T, Gustafson CE. Cellular mechanisms of aquaporin trafficking. Am J Physiol. 1998;275:F328–31.PubMed Brown D, Katsura T, Gustafson CE. Cellular mechanisms of aquaporin trafficking. Am J Physiol. 1998;275:F328–31.PubMed
3.
go back to reference Kanno K, Sasaki S, Hirata Y, Ishikawa S, Fushimi K, Nakanishi S, et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med. 1995;332:1540–5.PubMedCrossRef Kanno K, Sasaki S, Hirata Y, Ishikawa S, Fushimi K, Nakanishi S, et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med. 1995;332:1540–5.PubMedCrossRef
4.
go back to reference Rai T, Sekine K, Kanno K, Hata K, Miura M, Mizushima A, et al. Urinary excretion of aquaporin-2 water channel protein in human and rat. J Am Soc Nephrol. 1997;8:1357–62.PubMed Rai T, Sekine K, Kanno K, Hata K, Miura M, Mizushima A, et al. Urinary excretion of aquaporin-2 water channel protein in human and rat. J Am Soc Nephrol. 1997;8:1357–62.PubMed
5.
go back to reference Elliot S, Goldsmith P, Knepper M, Haughey M, Olson B. Urinary excretion of aquaporin-2 in humans: a potential marker of collecting duct responsiveness to vasopressin. J Am Soc Nephrol. 1996;7:403–9.PubMed Elliot S, Goldsmith P, Knepper M, Haughey M, Olson B. Urinary excretion of aquaporin-2 in humans: a potential marker of collecting duct responsiveness to vasopressin. J Am Soc Nephrol. 1996;7:403–9.PubMed
6.
go back to reference Deen PM, van Aubel RA, van Lieburg AF, van Os CH. Urinary content of aquaporin 1 and 2 in nephrogenic diabetes insipidus. J Am Soc Nephrol. 1996;7:836–41.PubMed Deen PM, van Aubel RA, van Lieburg AF, van Os CH. Urinary content of aquaporin 1 and 2 in nephrogenic diabetes insipidus. J Am Soc Nephrol. 1996;7:836–41.PubMed
7.
go back to reference Pedersen RS, Bentzen H, Bech JN, Pedersen EB. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol. 2001;280:F860–7.PubMed Pedersen RS, Bentzen H, Bech JN, Pedersen EB. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol. 2001;280:F860–7.PubMed
8.
go back to reference Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol. 1999;10:2165–70.PubMed Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol. 1999;10:2165–70.PubMed
9.
go back to reference Ivarsen P, Frøkiaer J, Aagaard NK, Hansen EF, Bendtsen F, Nielsen S, et al. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. Gut. 2003;52:1194–9.PubMedCrossRef Ivarsen P, Frøkiaer J, Aagaard NK, Hansen EF, Bendtsen F, Nielsen S, et al. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. Gut. 2003;52:1194–9.PubMedCrossRef
10.
go back to reference Ishikawa Se, Saito T, Fukagawa A, Higashiyama M, Nakamura T, Kusaka I, et al. Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. J Clin Endocrinol Metab. 2001;86:1665–71.CrossRef Ishikawa Se, Saito T, Fukagawa A, Higashiyama M, Nakamura T, Kusaka I, et al. Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. J Clin Endocrinol Metab. 2001;86:1665–71.CrossRef
11.
go back to reference Ranchin B, Boury-Jamot M, Blanchard G, Dubourg L, Hadj-Aïssa A, Morin D, et al. Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion. J Clin Endocrinol Metab. 2010;95:E37–43.PubMedCrossRef Ranchin B, Boury-Jamot M, Blanchard G, Dubourg L, Hadj-Aïssa A, Morin D, et al. Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion. J Clin Endocrinol Metab. 2010;95:E37–43.PubMedCrossRef
12.
go back to reference Umenishi F, Summer SN, Cadnapaphornchai M, Schrier RW. Comparison of three methods to quantify urinary aquaporin-2 protein. Kidney Int. 2002;62:2288–93.PubMedCrossRef Umenishi F, Summer SN, Cadnapaphornchai M, Schrier RW. Comparison of three methods to quantify urinary aquaporin-2 protein. Kidney Int. 2002;62:2288–93.PubMedCrossRef
13.
go back to reference Iacobelli S, Gouyon JB, Bonsante F, Mastrofrancesco L, Svelto M, Valenti G. Aquaporin-2 urinary excretion in preterm infants: relationship to diuresis and vasopressin. Acta Physiol. 2010;200:339–45.CrossRef Iacobelli S, Gouyon JB, Bonsante F, Mastrofrancesco L, Svelto M, Valenti G. Aquaporin-2 urinary excretion in preterm infants: relationship to diuresis and vasopressin. Acta Physiol. 2010;200:339–45.CrossRef
14.
go back to reference Tanaka K, Ishikawa E, Ohmoto Y, Hirai Y. In vitro production of human interleukin 1 alpha and interleukin 1 beta by peripheral blood mononuclear cells examined by sensitive sandwich enzyme immunoassay. Eur J Immunol. 1987;17:1527–30.PubMedCrossRef Tanaka K, Ishikawa E, Ohmoto Y, Hirai Y. In vitro production of human interleukin 1 alpha and interleukin 1 beta by peripheral blood mononuclear cells examined by sensitive sandwich enzyme immunoassay. Eur J Immunol. 1987;17:1527–30.PubMedCrossRef
15.
go back to reference Saito T, Ishikawa SE, Sasaki S, Nakamura T, Rokkaku K, Kawakami A, et al. Urinary excretion of aquaporin-2 in the diagnosis of central diabetes insipidus. J Clin Endocrinol Metab. 1997;82:1823–7.PubMedCrossRef Saito T, Ishikawa SE, Sasaki S, Nakamura T, Rokkaku K, Kawakami A, et al. Urinary excretion of aquaporin-2 in the diagnosis of central diabetes insipidus. J Clin Endocrinol Metab. 1997;82:1823–7.PubMedCrossRef
16.
go back to reference Pedersen RS, Bentzen H, Bech JN, Nyvad O, Pedersen EB. Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. Kidney Int. 2003;63:1417–25.PubMedCrossRef Pedersen RS, Bentzen H, Bech JN, Nyvad O, Pedersen EB. Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. Kidney Int. 2003;63:1417–25.PubMedCrossRef
17.
go back to reference Lu WS, Xu DL, Yin XY, Ren H, Meng SR. Enzyme-linked immunosorbent assay for urinary aquaporin-2 water channel protein measurement. Di Yi Jun Yi Da Xue Xue Bao. 2002;22:486–9.PubMed Lu WS, Xu DL, Yin XY, Ren H, Meng SR. Enzyme-linked immunosorbent assay for urinary aquaporin-2 water channel protein measurement. Di Yi Jun Yi Da Xue Xue Bao. 2002;22:486–9.PubMed
18.
go back to reference Nakamura T, Saito T, Kusaka I, Higashiyama M, Nagasaka S, Ishibashi S, Ishikawa, et al. Decrease in urinary excretion of aquaporin-2 associated with impaired urinary concentrating ability in diabetic nephropathy. Nephron. 2002;92:445–8.PubMedCrossRef Nakamura T, Saito T, Kusaka I, Higashiyama M, Nagasaka S, Ishibashi S, Ishikawa, et al. Decrease in urinary excretion of aquaporin-2 associated with impaired urinary concentrating ability in diabetic nephropathy. Nephron. 2002;92:445–8.PubMedCrossRef
Metadata
Title
Daily variance of urinary excretion of AQP2 determined by sandwich ELISA method
Authors
Sei Sasaki
Yasukazu Ohmoto
Toyoki Mori
Fusako Iwata
Masahiro Muraguchi
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0574-2

Other articles of this Issue 3/2012

Clinical and Experimental Nephrology 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.